Humanized Immune-Checkpoint Mice

Cancer immunotherapy is one of the most promising research areas in the field of cancer therapy, with immuno-oncology mouse models at the helm of available research tools. Major pharmaceutical companies in the world have devoted great efforts to developing cancer immunity-related treatment methods, with clinical trial results showing that the treatment efficacy is very high. Furthermore, Science magazine ranked cancer immunotherapy to be first place among the top ten scientific breakthroughs in 2013.

Immune checkpoints are molecules in the immune system that either turn up (co-stimulatory molecules) or turn down (inhibitory molecules) immune signals. Tumors can use these checkpoints to protect themselves from immune system attacks, particularly by T cells. Checkpoint therapy can block inhibitory checkpoints or activate stimulatory molecules, restoring immune system function.  In recent years, immune checkpoint drugs have become an important novel cancer treatment, as have immuno-oncology mouse models. Biocytogen has prepared and validated a series of immune checkpoint humanized mice that can serve as immuno-oncology mouse models for in vivo efficacy evaluation of human immune checkpoint antibodies.

Key features of Biocytogen’s humanized immune checkpoint mice:

  • Pure C57BL/6 genetic background leads to more consistent and reliable experimental results. Biocytogen’s humanized immune checkpoint mice are all developed on the C57BL/6 genetic background, which is most commonly used in oncology, physiology, immunology and genetics studies.
  • The humanized mice are carefully designed and generated to maintain biological functions and ensure more reliable drug validation. Biocytogen has developed a wealth of experience in animal model development, with specific experience in humanized immuno-oncology mouse model design. Our project managers are well equipped to fully consider all factors that may interfere with the expression of humanized proteins and to design a detailed, scientifically accurate plan to ensure sufficient humanization, humanized protein expression, and intact signal transduction. With humanized mice, in vivo efficacy evaluation of humanized immune checkpoint antibodies or inhibitors becomes even more reliable and dependable.

Single Humanized Immune-checkpoint Mice

Product Product No Background
B-hB7-H3 mice 110028 C57BL/6
B-hBTLA mice 110005 C57BL/6
B-hC5AR1 Mice 110078 C57BL/6
B-hCCR8 mice 110096 C57BL/6
B-hCD226 mice 110869 C57BL/6
B-hCD27 mice 110006 C57BL/6
B-hCD28 mice 110007 C57BL/6
B-hCD38 mice 110046 C57BL/6
B-hCD39 mice 110792 C57BL/6
B-hCD3E mice 110008 C57BL/6
B-hCD40 mice 110009 C57BL/6
B-hCD47 (C) mice 110615 BALB/c
B-hCD47 mice 110010 C57BL/6
B-hCD73 mice 110027 C57BL/6
B-hCD73 mice plus 110047 C57BL/6
B-hCD94 Mice 110044 C57BL/6
B-hCTLA4 mice 110011 C57BL/6
B-hETAR mice 110108 C57BL/6
B-hHAVCR2 (TIM3) mice 110018 C57BL/6
B-hLAG3 mice 110013 C57BL/6
B-hLAG3 mice plus 110025 C57BL/6
B-hNKG2A mice 110041 C57BL/6
B-hOX40L mice 110043 C57BL/6
B-hPD-1 mice 110003 C57BL/6
B-hPD-1 mice Plus 110019 C57BL/6
B-hPD-L1 (CD274) mice 110015 C57BL/6
B-hSIRPα mice 110016 C57BL/6
B-hTIGIT mice 110017 C57BL/6
B-hTLR8 Mice 110104 C57BL/6
B-hTNFRSF18 (GITR) mice 110012 C57BL/6
B-hTNFRSF4 (OX40) mice 110014 C57BL/6
B-hTNFRSF9 (4-1BB) mice 110004 C57BL/6

Double Humanized Immune-checkpoint Mice

Product Product No Background
B-hCD94/hNKG2A mice 121077 C57BL/6
B-hCTLA4/h4-1BB mice 120539 C57BL/6
B-hCTLA4/hGITR Mice 120962 C57BL/6
B-hCTLA4/hLAG3 mice 120529 C57BL/6
B-hCTLA4/hOX40 mice 120531 C57BL/6
B-hCTLA4/hTIM3 mce 120530 C57BL/6
B-hIL12A/hIL12B mice PA190242 C57BL/6
B-hILl7A/hIL17F mice 120554 C57BL/6
B-hOX40/h4-1BB mice 120527 C57BL/6
B-hPD-1/h4-1BB mice 120516 C57BL/6
B-hPD-1/hBTLA mice 120517 C57BL/6
B-hPD-1/hCD27 mice 120518 C57BL/6
B-hPD-1/hCD40 mice 120526 C57BL/6
B-hPD-1/hCTLA4 mice 120519 C57BL/6
B-hPD-1/hGITR mice 120528 C57BL/6
B-hPD-1/hLAG3 mice 120520 C57BL/6
B-hPD-1/hOX40 mice 120521 C57BL/6
B-hPD-1/hPD-L1 mice 120522 C57BL/6
B-hPD-1/hTIGIT mice 120523 C57BL/6
B-hPD-1/hTIM3 mice 120524 C57BL/6
B-hPD-L1/h4-1BB mice 120535 C57BL/6
B-hPD-L1/hCD27 mice 120537 C57BL/6
B-hPD-L1/hCD40 mice 120536 C57BL/6
B-hPD-L1/hCTLA4 mice 120538 C57BL/6
B-hPD-L1/hLAG3 mice 120533 C57BL/6
B-hPD-L1/hOX40 mice 120534 C57BL/6
B-hPD-L1/hTIGIT mice 120532 C57BL/6
B-hPD-L1/hTIM3 mice 120540 C57BL/6
B-hSIRPα/hCD47 mice 120525 C57BL/6

Triple Humanized Immune-checkpoint Mice

Product Product No Background
B-hPD-1/hPD-L1/h4-1BB mice 130569 C57BL/6
B-hPD-1/hPD-L1/hCD40 mice 131083 C57BL/6
B-hPD-1/hPD-L1/hCTLA4 mice 130571 C57BL/6
B-hPD-1/hPD-L1/hCTLA4 mice 130571 C57BL/6
B-hPD-1/hPD-L1/hLAG3(plus) mice 130572 C57BL/6
B-hPD-1/hPD-L1/hTIGIT mice 130573 C57BL/6
B-hPD-1/hPD-L1/hTIM3 mice 130574 C57BL/6
B-hPD-1/hPD-L1/hTNFR2 mice 130849 C57BL/6
B-hPD-1/hSIRPA/hCD47 mice 130562 C57BL/6
B-hPD-L1/hSIRPA/hCD47 mice 130561 C57BL/6
B-hPD1/hLAG3/hTIM3 mice 130999 C57BL/6

Tetra Humanized Immune-checkpoint Mice

Product Product No Background
B-hPD-1/hPD-L1/hSIRPA/hCD47 mice 140577 C57BL/6

Other Humanized Mice

Product Product No Background
B-hA2AR mice 110120 C57BL/6
B-hCCR2 mice 110097 C57BL/6
B-hCCR4 mice 110098 C57BL/6
B-hFcRn mice 110001 C57BL/6
B-hTLR9 mice 110103 C57BL/6
Back to top